Enhanced cell growth and tumorigenicity of rat glioma cells by stable expression of human CD133 through multiple molecular actions

GLIA

Volumn 61, Issue 9, 2013, Pages 1402-1417

  Fang, Kuan Min ^a   Lin, Tzu Chien ^a   Chan, Ti Chun ^a   Ma, Shi Zhang ^a   Tzou, Bo Cheng ^a   Chang, Wen Ruei ^a   Liu, Jun Jen ^b   Chiou, Shih Hwa ^c   Yang, Chung Shi ^d   Tzeng, Shun Fen ^a  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

^d NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

Author keywords

Akt; Arhgap27; Arsenic trioxide; Glioma; Hes 1; Notch

Indexed keywords

ARSENIC TRIOXIDE; BMI1 PROTEIN; CD133 ANTIGEN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN; GUANOSINE TRIPHOSPHATASE ACTIVATING PROTEIN 27; LENTIVIRUS VECTOR; NOTCH1 RECEPTOR; PROTEIN KINASE B; TRANSCRIPTION FACTOR HES 1; TRANSCRIPTION FACTOR SOX2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BRAIN CORTEX; CARCINOGENESIS; CARCINOGENICITY; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLONOGENESIS; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; FEMALE; GENE EXPRESSION; GENE SILENCING; GENE TARGETING; GENETIC TRANSDUCTION; GLIOMA CELL; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; RAT; STABLE EXPRESSION; TUMOR GROWTH;

EID: 84880771285     PISSN: 08941491     EISSN: 10981136     Source Type: Journal    
DOI: 10.1002/glia.22521     Document Type: Article

References (52)

1. Angelastro JM, Lame MW. 2010. Overexpression of CD133 promotes drug resistance in C6 glioma cells. Mol Cancer Res 8:1105-1115.
2. Bao S, Wu Q, Sathornsumetee S, Hao Y, Li Z, Hjelmeland AB, Shi Q, McLendon RE, Bigner DD, Rich JN. 2006. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res 66:7843-7848.
3. Beier D, Hau P, Proescholdt M, Lohmeier A, Wischhusen J, Oefner PJ, Aigner L, Brawanski A, Bogdahn U, Beier CP. 2007. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Res 67:4010-4015.
4. Bernards A, Settleman J. 2004. GAP control: Regulating the regulators of small GTPases. Trends Cell Biol 14:377-385.
5. Bos JL, Rehmann H, Wittinghofer A. 2007. GEFs and GAPs: Critical elements in the control of small G proteins. Cell 129:865-877.
6. Campos B, Herold-Mende CC. 2010. Insight into the complex regulation of CD133 in glioma. Int J Cancer 128:501-510.
7. Campos B, Zeng L, Daotrong PH, Eckstein V, Unterberg A, Mairbaurl H, Herold-Mende C. 2011. Expression and regulation of AC133 and CD133 in glioblastoma. Glia 59:1974-1986.
8. Chang CJ, Hsu CC, Yung MC, Chen KY, Tzao C, Wu WF, Chou HY, Lee YY, Lu KH, Chiou SH, et al. 2009. Enhanced radiosensitivity and radiation-induced apoptosis in glioma CD133-positive cells by knockdown of SirT1 expression. Biochem Biophys Res Commun 380:236-242.
9. Chearwae W, Bright JJ. 2008. PPARgamma agonists inhibit growth and expansion of CD133+ brain tumour stem cells. Br J Cancer 99:2044-2053.
10. Chen R, Nishimura MC, Bumbaca SM, Kharbanda S, Forrest WF, Kasman IM, Greve JM, Soriano RH, Gilmour LL, Rivers CS, et al. 2010. A hierarchy of self-renewing tumor-initiating cell types in glioblastoma. Cancer Cell 17:362-375.
11. Chiu HW, Ho SY, Guo HR, Wang YJ. 2009. Combination treatment with arsenic trioxide and irradiation enhances autophagic effects in U118-MG cells through increased mitotic arrest and regulation of PI3K/Akt and ERK1/2 signaling pathways. Autophagy 5:472-483.
12. Clement V, Dutoit V, Marino D, Dietrich PY, Radovanovic I. 2009. Limits of CD133 as a marker of glioma self-renewing cells. Int J Cancer 125:244-248.
13. Clement V, Sanchez P, de Tribolet N, Radovanovic I, Ruiz i Altaba A. 2007. HEDGEHOG-GLI1 signaling regulates human glioma growth, cancer stem cell self-renewal, and tumorigenicity. Curr Biol 17:165-172.
14. Coskun V, Wu H, Blanchi B, Tsao S, Kim K, Zhao J, Biancotti JC, Hutnick L, Krueger RC Jr, Fan G, de Vellis J, Sun YE. 2008. CD133+ neural stem cells in the ependyma of mammalian postnatal forebrain. Proc Natl Acad Sci USA 105:1026-1031.
15. Dahmane N, Sanchez P, Gitton Y, Palma V, Sun T, Beyna M, Weiner H, Ruiz i Altaba A. 2001. The Sonic Hedgehog-Gli pathway regulates dorsal brain growth and tumorigenesis. Development 128:5201-5212.
16. Das P, Puri T, Jha P, Pathak P, Joshi N, Suri V, Sharma MC, Sharma BS, Mahapatra AK, Suri A, et al. 2011. A clinicopathological and molecular analysis of glioblastoma multiforme with long-term survival. J Clin Neurosci 18:66-70.
17. Dean M, Fojo T, Bates S. 2005. Tumour stem cells and drug resistance. Nat Rev Cancer 5:275-284.
18. Fan X, Khaki L, Zhu TS, Soules ME, Talsma CE, Gul N, Koh C, Zhang J, Li YM, Maciaczyk J, et al. 2010. NOTCH pathway blockade depletes CD133-positive glioblastoma cells and inhibits growth of tumor neurospheres and xenografts. Stem cells 28:5-16.
19. Fan X, Matsui W, Khaki L, Stearns D, Chun J, Li YM, Eberhart CG. 2006. Notch pathway inhibition depletes stem-like cells and blocks engraftment in embryonal brain tumors. Cancer Res 66:7445-7452.
20. Fang KM, Wang YL, Huang MC, Sun SH, Cheng H, Tzeng SF. 2011. Expression of macrophage inflammatory protein-1alpha and monocyte chemoattractant protein-1 in glioma-infiltrating microglia: involvement of ATP and P2X(7) receptor. J Neurosci Res 89:199-211.
21. Ferrandina G, Petrillo M, Bonanno G, Scambia G. 2009. Targeting CD133 antigen in cancer. Expert Opin Ther Targets 13:823-837.
22. Frank NY, Schatton T, Frank MH. 2010. The therapeutic promise of the cancer stem cell concept. J Clin Invest 120:41-50.
23. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, et al. 2007. Malignant astrocytic glioma: Genetics, biology, and paths to treatment. Genes Dev 21:2683-2710.
24. Jaszai J, Fargeas CA, Florek M, Huttner WB, Corbeil D. 2007. Focus on molecules: Prominin-1 (CD133). Exp Eye Res 85:585-586.
25. Joo KM, Kim SY, Jin X, Song SY, Kong DS, Lee JI, Jeon JW, Kim MH, Kang BG, Jung Y, et al. 2008. Clinical and biological implications of CD133-positive and CD133-negative cells in glioblastomas. Lab Invest 88:808-815.
26. Kim SK, Suh MR, Yoon HS, Lee JB, Oh SK, Moon SY, Moon SH, Lee JY, Hwang JH, Cho WJ, et al. 2005. Identification of developmental pluripotency associated 5 expression in human pluripotent stem cells. Stem cells 23:458-462.
27. Knights MJ, Kyle S, Ismail A. 2012. Characteristic features of stem cells in glioblastomas: From cellular biology to genetics. Brain Pathol 22:592-606.
28. Lee A, Kessler JD, Read TA, Kaiser C, Corbeil D, Huttner WB, Johnson JE, Wechsler-Reya RJ. 2005. Isolation of neural stem cells from the postnatal cerebellum. Nat Neurosci 8:723-729.
29. Liu G, Yuan X, Zeng Z, Tunici P, Ng H, Abdulkadir IR, Lu L, Irvin D, Black KL, Yu JS. 2006. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol Cancer 5:67.
30. Liu YP, Yang CS, Tzeng SF. 2008. Inhibitory regulation of glutamate aspartate transporter (GLAST) expression in astrocytes by cadmium-induced calcium influx. J Neurochem 105:137-150.
31. Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P. 2007. The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97-109.
32. Mak AB, Nixon AM, Kittanakom S, Stewart JM, Chen GI, Curak J, Gingras AC, Mazitschek R, Neel BG, Stagljar I, et al. 2012. Regulation of CD133 by HDAC6 promotes beta-catenin signaling to suppress cancer cell differentiation. Cell Rep 2:951-963.
33. Marzesco AM, Janich P, Wilsch-Brauninger M, Dubreuil V, Langenfeld K, Corbeil D, Huttner WB. 2005. Release of extracellular membrane particles carrying the stem cell marker prominin-1 (CD133) from neural progenitors and other epithelial cells. J Cell Sci 118(Pt 13):2849-2858.
34. Maw MA, Corbeil D, Koch J, Hellwig A, Wilson-Wheeler JC, Bridges RJ, Kumaramanickavel G, John S, Nancarrow D, Roper K, et al. 2000. A frameshift mutation in prominin (mouse)-like 1 causes human retinal degeneration. Hum Mol Genet 9:27-34.
35. Neuzil J, Stantic M, Zobalova R, Chladova J, Wang X, Prochazka L, Dong L, Andera L, Ralph SJ. 2007. Tumour-initiating cells vs. cancer 'stem' cells and CD133: What's in the name? Biochem Biophys Res Commun 355(4):855-859.
36. Ogden AT, Waziri AE, Lochhead RA, Fusco D, Lopez K, Ellis JA, Kang J, Assanah M, McKhann GM, Sisti MB, et al. 2008. Identification of A2B5+CD133- tumor-initiating cells in adult human gliomas. Neurosurgery 62:505-514; discussion 514-5.
37. Piccirillo SG, Binda E, Fiocco R, Vescovi AL, Shah K. 2009. Brain cancer stem cells. J Mol Med 87:1087-1095.
38. Raso A, Mascelli S, Biassoni R, Nozza P, Kool M, Pistorio A, Ugolotti E, Milanaccio C, Pignatelli S, Ferraro M, et al. 2011. High levels of PROM1 (CD133) transcript are a potential predictor of poor prognosis in medulloblastoma. Neuro Oncol 13:500-508.
39. Reya T, Morrison SJ, Clarke MF, Weissman IL. 2001. Stem cells, cancer, and cancer stem cells. Nature 414:105-111.
40. Sakakibara T, Nemoto Y, Nukiwa T, Takeshima H. 2004. Identification and characterization of a novel Rho GTPase activating protein implicated in receptor-mediated endocytosis. FEBS Lett 566:294-300.
41. Singh SK, Clarke ID, Hide T, Dirks PB. 2004a. Cancer stem cells in nervous system tumors. Oncogene 23:7267-7273.
42. Singh SK, Clarke ID, Terasaki M, Bonn VE, Hawkins C, Squire J, Dirks PB. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res 63:5821-5828.
43. Singh SK, Hawkins C, Clarke ID, Squire JA, Bayani J, Hide T, Henkelman RM, Cusimano MD, Dirks PB. 2004b. Identification of human brain tumour initiating cells. Nature 432:396-401.
44. Stupp R, Hegi ME, Mason WP, Van Den Bent MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B, Belanger K, et al. 2009. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10:459-466.
45. Stupp R, Mason WP, Van Den Bent MJ, Weller M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn U, et al. 2005. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Engl J Med 352:987-996.
46. Tcherkezian J, Lamarche-Vane N. 2007. Current knowledge of the large RhoGAP family of proteins. Biol Cell 99:67-86.
47. Uchida N, Buck DW, He D, Reitsma MJ, Masek M, Phan TV, Tsukamoto AS, Gage FH, Weissman IL. 2000. Direct isolation of human central nervous system stem cells. Proc Natl Acad Sci USA 97:14720-14725.
48. Wang J, Sakariassen PO, Tsinkalovsky O, Immervoll H, Boe SO, Svendsen A, Prestegarden L, Rosland G, Thorsen F, Stuhr L, et al. 2008. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int J Cancer 122:761-768.
49. Weigmann A, Corbeil D, Hellwig A, Huttner WB. 1997. Prominin, a novel microvilli-specific polytopic membrane protein of the apical surface of epithelial cells, is targeted to plasmalemmal protrusions of non-epithelial cells. Proc Natl Acad Sci USA 94:12425-12430.
50. Yin AH, Miraglia S, Zanjani ED, Almeida-Porada G, Ogawa M, Leary AG, Olweus J, Kearney J, Buck DW. 1997. AC133, a novel marker for human hematopoietic stem and progenitor cells. Blood 90:5002-5012.
51. Zhen Y, Zhao S, Li Q, Li Y, Kawamoto K. 2010. Arsenic trioxide-mediated Notch pathway inhibition depletes the cancer stem-like cell population in gliomas. Cancer Lett 292:64-72.
52. Zheng X, Shen G, Yang X, Liu W. 2007. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res 67:3691-3697.